Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry

Transfusion

Volumn 44, Issue 5, 2004, Pages 731-738

  Zavizion, Boris ^b   Pereira, Mercio ^b   De Melo Jorge, Milena ^b   Serebryanik, Diana ^b   Mather, Thomas N ^b   Chapman, John ^b   Miller, Nathan J ^b   Alford, Bernadette ^b   Bzik, David J ^b   Purmal, Andrei ^a  

^a VI Technologies Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZIRIDINE DERIVATIVE; NUCLEIC ACID; PEN 110; PROTOZOAL DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABESIA MICROTI; BLOOD SMEAR; BLOOD TRANSFUSION; CELL CULTURE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA DENATURATION; DRUG MECHANISM; ERADICATION THERAPY; ERYTHROCYTE; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; INACTINE TECHNOLOGY; MEDICAL TECHNOLOGY; NONHUMAN; PARASITE CULTIVATION; PARASITE DEVELOPMENT; PARASITE INACTIVATION; PARASITE TRANSMISSION; PARASITEMIA; PLASMODIUM FALCIPARUM; PROTOZOAL INFECTION; TRANSFUSION TRANSMITTED INFECTION; TRYPANOSOMA CRUZI;

ANIMALS; BABESIA MICROTI; ERYTHROCYTES; HUMANS; PLASMODIUM FALCIPARUM; POLYAMINES; TRYPANOSOMA CRUZI;

EID: 2342496703     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.03207.x     Document Type: Article

References (56)

1. Mehlhorn H, ed. Encyclopedic reference of parasitology. 2nd ed. Berlin: Springer-Verlag, 2001:75-7.
2. Hatcher JC, Greenberg PD, Antique J, et al. Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis 2001;32:1117-25.
3. Persing DH, Herwaldt BL, Glaser C, et al. Infection with a babesia-like organism in northern California. N Engl J Med 1995;332:298-303.
4. Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. J Infect Dis 1997;175:1259-62.
5. Herwaldt B, Persing DH, Precigout EA, et al. A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann Intern Med 1996;124:643-50.
6. Iacopino V, Earnhart T. Life-threatening babesiosis in a woman from Wisconsin. Arch Intern Med 1990;150:1527-8.
7. Healy GR, Walzer PD, Sulzer AJ. A case of asymptomatic babesiosis in Georgia. Am J Trop Med Hyg 1976;25:376-8.
8. Wei Q, Tsuji M, Zamoto A, et al. Human babesiosis in Japan: isolation of Babesia microti-like parasites from an asymptomatic transfusion donor and from a rodent from an area where babesiosis is endemic. J Clin Microbiol 2001;39:2178-83.
9. Brasseur P, Gorenflot A. Human babesiosis in Europe. Mem Inst Oswaldo Cruz 1992;87(Suppl 3):131-2.
10. Uguen C, Girard L, Brasseur P, et al. Human babesiosis in 1997. Rev Med Interne 1997;18:945-51.
11. Hunfeld KP, Lambert A, Kampen H, et al. Seroprevalence of Babesia infections in humans exposed to ticks in midwestern Germany. J Clin Microbiol 2002;40:2431-6.
12. Homer MJ, Aguilar-Delfin I, Telford SR, et al. Babesiosis Clin Microbiol Rev 2000;13:451-69.
13. Falagas ME, Klempner MS. Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Clin Infect Dis 1996;22:809-12.
14. Brigden ML. Detection, education and management of the asplenic or hyposplenic patient. Am Fam Physician 2001;63:499-506, 508.
15. Pantanowitz L, Telford SR, Cannon ME. The impact of babesiosis on transfusion medicine. Transfus Med Rev 2002;16:131-43.
16. Leiby DA, Chung AP, Triano LR, et al. Serologic and nucleic acid evidence for Babesia microti in Connecticut (CT) blood donors. Transfusion 2000;40:2S.
17. Cable RG, Badon S, Trouern-Trend J, et al. Evidence for transmission of Babesia microti from Connecticut blood donors to recipients. Transfusion 2001;41:12S.
18. Popovsky MA, Lindberg LE, Syrek AL, Page PL. Prevalence of Babesia antibody in a selected blood donor population. Transfusion 1988;28:59-61.
19. Eberhard ML, Walker EM, Steurer FJ. Survival and infectivity of Babesia in blood maintained at 25°C and 2-4°C. J Parasitol 1995;81:790-2.
20. Mintz ED, Anderson JF, Cable RG, Hadler JL. Transfusion-transmitted babesiosis: a case report from a new endemic area. Transfusion 1991;31:365-8.
21. Kjemtrup AM, Lee B, Fritz CL, et al. Investigation of transfusion transmission of a WA1-type babesial parasite to a premature infant in California. Transfusion 2002;42:1482-7.
22. Kain KC, Jassoum SB, Fong IW, Hannach B. Transfusion-transmitted babesiosis in Ontario: first reported case in Canada. CMAJ 2001;164:1721-3.
23. World malaria situation in 1994. Part I. Population at risk. Wkly Epidem Rec 1997;72:269-74.
24. Mehlhorn H, ed. Encyclopedic reference of parasitology. 2nd ed. Berlin: Springer-Verlag, 2001:492-3.
25. Morcos WM. Morphological observation on various stages of Plasmodium vivax and Plasmodium malariae in blood preserved by refrigeration for transfusion. Riv Malar 1961;40:41-50.
26. De Silva M, Contreras M, Barbara J. Two cases of transfusion-transmitted malaria (TTM) in the UK. Transfusion 1988;28:86.
27. Kark JA. Malaria transmitted by blood transfusion. In: Tabor E, ed. Infectious complications of blood transfusion. New York: Academic Press, 1982:93-126.
28. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001;344:1973-8.
29. Bruce-Chwatt LJ. Transfusion malaria revisited. Trop Dis Bull 1982;79:827-40.
30. Slinger R, Giulivi A, Bodie-Collins M, et al. Transfusion-transmitted malaria in Canada. CMAJ 2001;164:377-9.
31. Besson P, Robert JF, Reviron J, et al. [Two cases of transfusional malaria. Attempted prevention combining an indirect immunofluorescence test with clinical selection criteria.] Rev Fr Transfus Immunohematol 1976;19:369-73.
32. Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of donor blood selection criteria for United States travelers to malarious areas. Transfusion 1991;31:798-804.
33. Schmunis GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991;31:547-57.
34. Control of Chagas disease. Report of a WHO Expert Committee. WHO Tech Rep Series 1991;811:1-95.
35. Kirchhoff LV. Trypanosoma species (American trypanosomiasis, Chagas disease): biology of trypanosomes. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990:2077-84.
36. Mehlhorn H, ed. Encyclopedic reference of parasitology. 2nd ed. Berlin: Springer-Verlag, 2001:648, 653-4.
37. Shulman IA. Intervention strategies to reduce the risk of transfusion-transmitted Trypanosoma cruzi infection in the United States. Transfus Med Rev 1999;13:227-34.
38. Lane DJ, Sher G, Ward B, et al. Investigation of the second case of transfusion transmitted Chagas' disease in Canada (abstract). Blood 2000;96:60a.
39. Schmunis GA. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Mem Inst Oswaldo Cruz 1999;94(Suppl 1):93-101.
40. Freitas JLP, Amato V, Sonntag R, et al. First verification of accidental transmission of Chagas disease to the human by blood transfusion. Rev Paul Med 1952;40:36-40.
41. Carrasco R, Miguez H, Camacho C, et al. Prevalence of Trypanosoma cruzi infection in blood banks of seven departments of Bolivia. Mem Inst Oswaldo Cruz 1990;85:69-73.
42. Schmunis GA, Zicker F, Cruz JR, Cuchi P. Safety of blood supply for infectious diseases in Latin American countries, 1994-97. Am J Trop Med Hyg 2001;65:924-30.
43. Lazo A, Tassello J, Jayarama V, et al. A broad spectrum virus reduction in red cell concentrates using INACTINE™ PEN110 chemistry. Vox Sang 2002;83:313-23.
44. Ohagen A, Gibaja V, Aytay S, et al. Inactivation of the human immunodeficiency virus in blood. Transfusion 2002;42:1308-17.
45. Zavizion B, Serebryanik D, Serebryanik I, et al. Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process. Transfusion 2003;43:135-42.
46. Chapman J. Progress in improving the pathogen safety of red cell concentrates. Vox Sang 2000;78(Suppl 2):203-4.
47. Purmal A, Valeri CR, Dzik W, et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002;42:139-45.
48. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion 2002;42:146-52.
49. Fast LD, DiLeone G, Edson CM, Purmal A. Inhibition of murine GVHD by PEN110 treatment. Transfusion 2002;42:1326-32.
50. Fast LD, DiLeone G, Edson CM, Purmal A. PEN110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to γ-irradiation. Transfusion 2002;42:1318-25.
51. Chapman J, Fisher B, Moor K. The viral inactivation compound INACTINE™ PEN110 lacks reproductive toxicity in rabbits. Vox Sang 2002;83:191.
52. Hemminki K. Reactions of ethyleneimine with guanosine and deoxyguanosine. Chem Biol Interacts 1984;48:249-60.
53. Budowsky EI, Zalesskaya MA, Nepomnyashchaya NM, Kostyanovsky RG. Principals of selective inactivation of the viral genome: dependence of the rate of viral RNA modification on the number of protonizable groups in ethyleneimine oligomers. Vaccine Res 1996;5:29-39.
54. O'Connor TR, Boiteux S, Laval J. Ring-opened 7-methylguanine residues in DNA are a block to in vitro DNA synthesis. Nucl Acid Res 1988;16:5879-94.
55. Krause PJ, Telford S, Spielman A, et al. Comparison of PCR with blood smear and inoculation of small animals for diagnosis of Babesia microti parasitemia. J Clin Microbiol 1996;34:2791-4.
56. Fox BA, Bzik DJ. Analysis of stage-specific transcripts of the Plasmodium falciparum serine repeat antigen (SERA) gene and transcription from the SERA locus. Mol Biochem Parasitol 1994;68:133-44.